From: CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool
Variant | PAM sequence (5′–3′) | Utilization | Ref. |
---|---|---|---|
SpCas9 | NGG | Multiplex genome editing in mammalian cells | [265] |
SpCas9-VRER | NGCG | Editing previously inaccessible sites in zebrafish embryos as well as human cells | [269] |
SaCas9 | NNGRRT | More efficient genome edition by the AAV-SaCas9-gRNA vector system | [270] |
CjCas9 | NNNVRYM | In vivo genome edition within muscles of dystrophin KO mice | [271] |
SpCas9-NG | NG | More efficient and accurate genome edition in mouse zygotes and also somatic culture cells | [272] |
evoCas9 | NGG | Restricting unspecific cleavage of a difficult-to-discriminate off-target region and fully perturbing the cleavage of two additional off-targets | [273] |
xCas9–3.7 | NG, GAA, GAT | Base replacement of C.G → T.A and A.T → G.C for pathogenic mutation sites | [274] |
SpRY | NA | Exact editing extending to almost the whole genome | [275] |